Liquid Embolic Agents Market Research Report, Analysis and Forecast – (2021 – 2028)

Liquid Embolic Agents Market Trends Driving Global Adoption 

The Liquid Embolic Agents Market is undergoing a transformative phase, driven by rapid advancements in minimally invasive neurovascular procedures and growing incidences of cerebral aneurysms. The rise in ischemic and hemorrhagic stroke cases, particularly in aging populations, is propelling clinical adoption of embolization therapies. For instance, the World Stroke Organization estimates over 12 million new strokes occur globally each year, with nearly 60% attributed to hemorrhagic causes that require urgent embolization. In response, hospitals and specialized neurosurgical centers are increasingly integrating liquid embolic agents into their interventional toolkits, directly boosting the Liquid Embolic Agents Market. 

Innovation remains a crucial factor in shaping market momentum. Novel agents like ethylene-vinyl alcohol copolymer (EVOH)-based products have demonstrated superior performance in complex intracranial aneurysms. These materials offer enhanced visibility under fluoroscopy and better penetration into vascular malformations, streamlining surgical workflows. As such, the Liquid Embolic Agents Market is benefiting from both procedural efficiencies and clinical success rates. 

Liquid Embolic Agents Market Growth Catalyzed by Rising Neurovascular Interventions 

The Liquid Embolic Agents Market is being catalyzed by a steep rise in neurovascular interventions globally. Data from the National Inpatient Sample (USA) indicates that endovascular treatment for aneurysms has risen by over 30% between 2015 and 2021. With embolization now considered a front-line treatment for arteriovenous malformations (AVMs), demand for liquid agents like Onyx and Squid has surged. These agents enable deep tissue penetration and effective lesion occlusion, making them indispensable in complex procedures. 

In emerging markets across APAC, a 22% CAGR in neuro-intervention procedures from 2018 to 2023 is being observed, particularly in India and China. These nations are experiencing heightened demand due to expanding access to advanced neurology care and increased government healthcare expenditure. Consequently, the Liquid Embolic Agents Market is experiencing its highest growth rate in this region, where minimally invasive procedures are increasingly prioritized. 

Liquid Embolic Agents Market Demand Boosted by Expanding Oncology Applications 

The expanding application of liquid embolic agents in oncology is redefining the scope of the Liquid Embolic Agents Market. Transarterial chemoembolization (TACE) procedures for treating liver cancer, for instance, are becoming more reliant on liquid embolics to achieve durable vascular occlusion. According to Datavagyanik, hepatocellular carcinoma (HCC) represents over 75% of all primary liver cancers globally, and nearly 60% of these patients are eligible for embolization therapies. 

In Japan, over 25,000 TACE procedures are performed annually, with liquid agents becoming the material of choice due to their controlled delivery and reduced risk of non-target embolization. Similarly, in the US and Europe, where the liver cancer burden is growing among aging populations, the Liquid Embolic Agents Market is gaining traction through oncology-related use cases. This trend underlines the market’s diversification beyond neurology. 

Liquid Embolic Agents Market Influenced by Evolving Reimbursement Structures 

Another key trend in the Liquid Embolic Agents Market is the shift in reimbursement frameworks that favor minimally invasive and cost-effective therapies. For instance, CMS in the United States revised its payment structure in 2020 to include specific coding for intracranial embolization procedures, ensuring higher reimbursement for facilities using advanced embolic agents. This change has significantly improved the economics for hospitals, encouraging the adoption of liquid agents over traditional coil embolization. 

In Western Europe, similar reimbursement models are evolving in countries like Germany and the UK, where procedure bundling has begun to recognize the value of modern embolic materials. This is directly enhancing the Liquid Embolic Agents Market Size, especially in tertiary care and academic hospitals that often serve as early adopters of innovative medical devices. 

Liquid Embolic Agents Market Supported by Technological Advancements in Imaging 

Technological synergy between liquid embolic agents and real-time imaging systems is further fueling the Liquid Embolic Agents Market. Innovations in fluoroscopy, digital subtraction angiography (DSA), and MRI-compatible catheter systems are enabling more precise delivery of agents into microvasculature. For example, new radiopaque formulations enhance visibility, allowing interventional radiologists to monitor agent flow and avoid complications. 

Such integration of agent properties with imaging capabilities is accelerating procedural confidence and widening the scope of indications. Hospitals are increasingly favoring agents that offer both safety and superior visualization, ensuring predictable outcomes. This evolution aligns with Datavagyanik’s insights that link technological convergence with heightened market demand across developed and developing economies. 

Liquid Embolic Agents Market Size Expansion Through Strategic Partnerships and R&D 

Strategic partnerships and R&D investments are playing a critical role in expanding the Liquid Embolic Agents Market Size. Major medtech companies are entering co-development agreements with research institutions to develop next-generation embolic agents that offer faster polymerization, reduced toxicity, and enhanced stability. For instance, partnerships between European biotech firms and global catheter manufacturers are producing hybrid agents with dual-modality applications in neurology and oncology. 

These collaborations are enabling faster clinical approvals and regulatory filings. As of 2023, over 12 new liquid embolic formulations were in advanced stages of clinical trials, targeting diverse indications from AVMs to gastrointestinal bleeding. With pipeline innovation intensifying, the Liquid Embolic Agents Market is witnessing continuous product refresh cycles, each contributing to market expansion and deeper penetration. 

Liquid Embolic Agents Market Penetration Enhanced by Training and Skill Development Programs 

The Liquid Embolic Agents Market is also benefiting from increased training programs and fellowships in interventional neuroradiology and oncology. Institutions such as the European Society of Minimally Invasive Neurological Therapy (ESMINT) and the Society of Interventional Radiology (SIR) have ramped up skill enhancement workshops focused on liquid embolic agent usage. 

By equipping physicians with advanced hands-on training and digital simulators, these programs are accelerating procedural adoption and minimizing complications. As clinician confidence grows, the Liquid Embolic Agents Market is seeing expanded utilization, particularly in secondary hospitals and regional healthcare networks where expertise was previously limited. 

Liquid Embolic Agents Market Expansion Driven by Demand in Emergency and Trauma Care 

The rising incidence of emergency trauma and gastrointestinal bleeding cases is fueling another demand segment within the Liquid Embolic Agents Market. These agents are proving critical in managing acute bleeds where rapid hemostasis is required. For instance, in trauma centers across the United States, liquid embolization is now a first-line treatment for pelvic fractures and vascular lacerations, thanks to its quick action and minimally invasive nature. 

Global trauma data indicates a 10–12% rise in vascular injuries requiring embolization from 2017 to 2022, particularly in regions experiencing high road traffic fatalities and conflict. This shift is opening new channels of growth for the Liquid Embolic Agents Market beyond traditional neurological applications. 

Liquid Embolic Agents Market Trends in Pediatric and Rare Disease Treatment 

The Liquid Embolic Agents Market is also witnessing a growing role in pediatric interventions and the treatment of rare vascular disorders. Conditions like vein of Galen malformations and hereditary hemorrhagic telangiectasia (HHT) often require delicate embolization strategies. Pediatric interventional centers in North America and Europe are increasingly adopting low-viscosity liquid agents that are safer for use in neonates and children. 

Datavagyanik’s analysis shows that the number of pediatric embolization procedures grew by 18% between 2020 and 2023, driven by enhanced awareness, improved diagnostic tools, and better procedural outcomes. This niche segment is expected to have a disproportionately high impact on the overall Liquid Embolic Agents Market in terms of clinical innovation and ethical trial design. 

“Track Country-wise Liquid Embolic Agents Production and Demand through our Liquid Embolic Agents Production Database”

• • • Liquid Embolic Agents production database for 28+ countries worldwide
    • Liquid Embolic Agents Powder sales volume for 32+ countries
    • Country-wise Liquid Embolic Agents production capacity and production plant mapping, production capacity utilization for 28+ manufacturers
    • Liquid Embolic Agents production plants and production plant capacity analysis for top manufacturers

Liquid Embolic Agents Market Geographical Demand Dynamics 

The Liquid Embolic Agents Market exhibits varying growth patterns across different geographies, with demand shaped by regional healthcare infrastructure, patient demographics, and the prevalence of target diseases. In North America, the Liquid Embolic Agents Market commands a dominant share due to the high concentration of tertiary care hospitals and a strong ecosystem of interventional radiology specialists. For instance, in the United States alone, over 18,000 intracranial aneurysm embolization procedures were performed in 2021, representing a 12% increase over the previous two years. This growth directly correlates with increased procurement of advanced liquid embolics, particularly in urban neurosurgical centers. 

In Canada, demand is being driven by expanded insurance coverage for endovascular treatments under provincial health plans. Additionally, the presence of leading academic centers such as Toronto Western Hospital has enabled wider adoption of liquid embolics for both clinical care and trials. As a result, the Liquid Embolic Agents Market in North America is anticipated to grow at a CAGR of over 8.5% through 2028, with the United States contributing more than 75% of the regional revenue. 

Europe Liquid Embolic Agents Market Fueled by Clinical Standardization 

Europe’s Liquid Embolic Agents Market is steadily expanding, supported by well-established regulatory pathways and consistent reimbursement frameworks. Countries such as Germany, France, and the UK are leading in the deployment of liquid embolics across neurology and interventional oncology. For example, in Germany, embolization has become the preferred treatment for over 60% of patients with arteriovenous malformations, due to national guidelines that promote minimally invasive treatment pathways. 

Clinical standardization through initiatives like the European Stroke Organisation’s certification program has helped streamline procedural protocols, thereby accelerating demand. In France, the use of liquid embolics in treating spinal AVMs has increased by 28% between 2018 and 2023, highlighting the market’s growth beyond cranial applications. The Liquid Embolic Agents Market in Europe is also experiencing robust support from public-private research partnerships focused on device innovation, thus fueling continuous clinical adoption. 

APAC Liquid Embolic Agents Market Accelerated by Infrastructure Expansion 

The Asia-Pacific Liquid Embolic Agents Market is growing at the fastest rate globally, driven by substantial healthcare infrastructure development and an increase in early diagnostic capabilities. Countries like China and India are seeing an upsurge in neurovascular interventions, attributed to a rising middle class and increased investment in specialized hospital networks. For instance, in China, Datavagyanik data shows that neurointerventional procedures grew by over 35% between 2019 and 2023, largely driven by government healthcare reforms under the “Healthy China 2030” initiative. 

Japan and South Korea have historically led in the region, benefiting from early adoption of embolic technologies and strong domestic R&D. In India, where stroke prevalence is now at 1.5 million new cases annually, major metro hospitals such as AIIMS and Apollo Hospitals are integrating liquid embolics into routine neurointerventions. As accessibility and awareness rise in Tier II cities, the Liquid Embolic Agents Market in APAC is projected to witness a double-digit CAGR over the next five years. 

Middle East & Latin America Liquid Embolic Agents Market Emerging Opportunities 

In the Middle East and Latin America, the Liquid Embolic Agents Market is still in its emerging phase but presents high potential. In Brazil, increased funding for public health programs and the expansion of interventional radiology training centers are creating fertile ground for liquid embolic adoption. Notably, the number of endovascular procedures in Brazil rose by 19% from 2020 to 2023, and this upward trend continues to support market entry by global and local suppliers. 

In the UAE and Saudi Arabia, growing investments in neurology departments and medical tourism are facilitating quicker adoption of cutting-edge treatments. Hospital groups in Dubai, for example, are actively collaborating with Western medtech firms to implement new embolic techniques, which is expected to drive the Liquid Embolic Agents Market in the region by 7–9% CAGR over the forecast period. 

Liquid Embolic Agents Manufacturing Driven by Innovation and Customization 

Liquid Embolic Agents Manufacturing has evolved from basic polymer production to a complex, precision-driven process involving radiopaque formulation, viscosity control, and catheter delivery optimization. Global manufacturing hubs are concentrated in North America and Western Europe, where stringent regulatory standards and robust IP protection frameworks incentivize innovation. 

Datavagyanik highlights that the majority of Liquid Embolic Agents Manufacturing currently involves proprietary blends of ethylene-vinyl alcohol copolymers, tantalum powder, and DMSO. Companies are increasingly adopting closed-system production methods to reduce contamination risks and ensure consistent agent behavior in clinical settings. In recent years, over $150 million in manufacturing CAPEX has been committed by leading players to scale production and refine compound stability for emerging applications. 

Localized Liquid Embolic Agents Manufacturing Rising in APAC 

An important trend is the rise of localized Liquid Embolic Agents Manufacturing in APAC countries, driven by import substitution policies and growing domestic demand. For example, China has accelerated approvals for homegrown embolic agents through its “Made in China 2025” strategy, encouraging joint ventures between local biotech firms and international technology providers. India has also seen the emergence of indigenous liquid embolic development, particularly from contract manufacturing organizations (CMOs) that cater to export markets. 

Such developments are not only reducing dependence on imports but also helping lower procedural costs in these regions, thereby broadening market access. Local Liquid Embolic Agents Manufacturing units are also playing a role in shortening lead times and enhancing product customization based on local clinical practices. 

Liquid Embolic Agents Market Segmentation by Application and End-Use 

The Liquid Embolic Agents Market is segmented based on application into neurology, oncology, trauma, and other vascular conditions. Neurology remains the largest segment, accounting for nearly 65% of the total market share. Applications such as AVM embolization, aneurysm occlusion, and fistula management continue to dominate. However, oncology is emerging as the fastest-growing segment with a CAGR of 12% over the forecast period, led by TACE procedures for liver and renal cancers. 

By end-user, hospitals represent the largest revenue contributor in the Liquid Embolic Agents Market, particularly large multispecialty institutions with advanced interventional radiology units. Ambulatory surgical centers (ASCs) are gradually adopting these agents as they move toward more complex outpatient procedures. Furthermore, academic institutions are playing a pivotal role in training and product validation, thereby expanding the overall user base. 

Liquid Embolic Agents Market Segmentation by Product Type 

Product segmentation in the Liquid Embolic Agents Market includes EVOH-based agents, cyanoacrylate compounds, and other emerging bio-based agents. EVOH-based products such as Onyx and Squid remain the most widely used, given their controlled precipitation properties and radiopacity. Cyanoacrylates are preferred in rapid hemostasis situations, particularly in trauma and gastrointestinal bleeding cases. 

Emerging product categories include biodegradable embolic agents and drug-eluting embolics, designed to release therapeutic payloads while achieving occlusion. Datavagyanik estimates that these advanced product types will constitute over 10% of the Liquid Embolic Agents Market by 2028, supported by ongoing clinical trials and regulatory approvals. 

Liquid Embolic Agents Market Pricing Trend and Cost Drivers 

The Liquid Embolic Agents Market has witnessed steady price evolution driven by raw material costs, regulatory compliance, and product innovation. Premium agents used in neurointerventions can cost upwards of $900–$1,200 per vial in North America and Europe. Factors influencing price include agent composition, visibility under imaging, and catheter compatibility. 

In contrast, emerging markets such as India and Brazil have lower pricing thresholds, with locally manufactured agents priced 30–40% lower due to reduced logistics costs and favorable tax regimes. Datavagyanik identifies regulatory harmonization and economies of scale as the primary levers to control pricing without compromising quality. For example, bulk procurement under public health schemes in Asia has resulted in negotiated discounts, improving affordability for state-run hospitals. 

In recent years, competitive dynamics have begun to exert downward pressure on prices, particularly as more players enter the Liquid Embolic Agents Market with equivalent or superior formulations. However, innovation-driven pricing remains sustainable in high-income regions where procedural outcomes and agent performance are the dominant purchasing criteria. 

“Liquid Embolic Agents Manufacturing Database, Liquid Embolic Agents Manufacturing Capacity”

• • • Liquid Embolic Agents top manufacturers market share for 28+ manufacturers
    • Top 8 manufacturers and top 18 manufacturers of Liquid Embolic Agents in North America, Europe, Asia Pacific
    • Production plant capacity by manufacturers and Liquid Embolic Agents production data for 28+ market players
    • Liquid Embolic Agents production dashboard, Liquid Embolic Agents production data in excel format

 

Leading Manufacturers in the Liquid Embolic Agents Market 

The Liquid Embolic Agents Market is characterized by the presence of several key manufacturers who have established themselves through innovative product offerings and strategic market positioning. These companies have contributed significantly to the advancement of embolization therapies, particularly in neurovascular and oncological applications. 

Medtronic 

Medtronic stands as a prominent player in the Liquid Embolic Agents Market, primarily due to its flagship product, the Onyx Liquid Embolic System. Onyx, composed of ethylene-vinyl alcohol copolymer (EVOH), is widely utilized for the embolization of brain arteriovenous malformations (AVMs) and aneurysms. The product’s non-adhesive properties and controlled delivery mechanism have made it a preferred choice among interventional radiologists. Medtronic’s commitment to research and development has further solidified its position in the market. 

Johnson & Johnson (Cerenovus) 

Cerenovus, a division of Johnson & Johnson, has made significant contributions to the Liquid Embolic Agents Market with its TRUFILL n-BCA Liquid Embolic System. This n-butyl cyanoacrylate (n-BCA) based agent is known for its rapid polymerization and strong adhesive properties, making it effective in the treatment of cerebral AVMs. The company’s focus on expanding its neurovascular portfolio has enhanced its market share and global reach. 

MicroVention Inc. (Terumo Corporation) 

MicroVention, a subsidiary of Terumo Corporation, offers the PHIL (Precipitating Hydrophobic Injectable Liquid) Embolic System. PHIL is distinguished by its hydrophobic properties and radiopacity, allowing for precise visualization during procedures. Its unique formulation enables deep penetration into vascular malformations, making it suitable for complex neurovascular interventions. MicroVention’s emphasis on innovation has positioned it as a key competitor in the market. 

Stryker Corporation 

Stryker has established a strong presence in the Liquid Embolic Agents Market through its acquisition of Surpass Medical and the subsequent development of the Surpass Streamline Flow Diverter. While primarily a flow-diverting stent, Stryker’s integration of embolic technologies has expanded its neurovascular treatment options. The company’s strategic acquisitions and product diversification have contributed to its growing market share. 

Balt Extrusion 

Balt Extrusion, a French company, specializes in the development of neurovascular devices, including liquid embolic agents. Its Squid Liquid Embolic System, available in various viscosities, offers flexibility in treating a range of vascular lesions. The product’s compatibility with different catheter systems and its cohesive properties have garnered attention in the interventional community. Balt’s focus on tailored solutions has enhanced its competitiveness in the market. 

Penumbra Inc. 

Penumbra has entered the Liquid Embolic Agents Market with its embolic platform designed for peripheral and neurovascular applications. The company’s emphasis on developing detachable coil systems and liquid embolics has expanded treatment options for patients with complex vascular conditions. Penumbra’s commitment to advancing minimally invasive therapies has contributed to its growing influence in the market. 

Market Share Distribution Among Manufacturers 

The Liquid Embolic Agents Market is segmented among these leading manufacturers, each holding varying degrees of market share based on product offerings, geographical presence, and clinical adoption. 

• Medtronic maintains a significant share, attributed to the widespread use of Onyx in neurovascular procedures. 

• Johnson & Johnson (Cerenovus) holds a substantial portion of the market, particularly in regions where TRUFILL n-BCA is the preferred embolic agent. 

• MicroVention Inc. has captured a notable share through the adoption of PHIL in complex interventions. 

• Stryker Corporation and Balt Extrusion have secured their positions by offering specialized products catering to specific clinical needs. 

• Penumbra Inc. continues to expand its market presence through innovative embolic solutions. 

Recent Developments and Industry Trends 

The Liquid Embolic Agents Market has witnessed several notable developments aimed at enhancing treatment efficacy and expanding therapeutic indications. 

• In March 2024, Cerenovus launched an updated TRUFILL n-BCA Liquid Embolic System Procedural Set, streamlining the preparation process for hemorrhagic stroke interventions. 

• Sirtex Medical introduced the LAVA Liquid Embolic System in October 2023, designed for peripheral vascular hemorrhage treatment, offering variable viscosity options for targeted vessel occlusion. 

• Balt Extrusion expanded its operational capabilities by opening a second office in France in June 2022, focusing on sales, marketing, and clinical affairs to support its growing product portfolio. 

These developments reflect the industry’s commitment to advancing embolization therapies, improving patient outcomes, and addressing unmet clinical needs. 

Liquid Embolic Agents Production Data and Liquid Embolic Agents Production Trend, Liquid Embolic Agents Production Database and forecast

• • • • Liquid Embolic Agents production database for historical years, 10 years historical data
      • Liquid Embolic Agents production data and forecast for next 7 years